pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Psychiatry & CNS · news · pharmadog
← back to Psychiatry & CNS
News · Psychiatry & CNS
440
stories
16d
With pioneering ADHD data, Alkermes eyes orexin agonist as potential ‘company changer’
fiercebiotech
16d
Opinion: More young men are coming to me for plastic surgery. The way I think about them has changed
stat
16d
Xenon pauses phase 3 depression trials after psychosis events
fiercebiotech
17d
This Week at FDA: Overton nomination hearing, FDA’s hiring challenges, and more
raps
17d
Kennedy announces new effort to speed up autism diagnoses
stat
17d
Purer fentanyl won’t solve the U.S. overdose death crisis, study says
stat
17d
STAT+: Zocdoc for chatbots and what’s new with Medicare’s ACCESS
stat
17d
Opinion: What happened to oppositional defiant disorder?
stat
17d
Trending: Top biopharma disciplines with jobs live now
biospace
18d
STAT+: Scientists made mice with half a brain. Then they filled them with human organoids
stat
18d
Deep dive: Psychedelics back on FDA’s doorstep
biospace
19d
STAT+: Medicare to expand its pilot that pays for technology to manage chronic diseases
stat
19d
Stakeholders urge FDA to define data, treatment standards as psychedelic drugs near market
biospace
19d
STAT+: New documents reveal problems with Medicare’s prior-authorization pilot
stat
19d
Contineum, J&J's drug fails in mid-stage depression trial
endpoints
19d
FDA should require credentials for psychedelic providers, experts say
endpoints
19d
Lilly pledges up to $237M per program in CNS genetic med collab with Canadian biotech
fiercebiotech
20d
As ‘cultural weight’ of a psychedelic approval looms, FDA hearing focuses on access and safety
fiercebiotech
20d
Definium moves toward FDA submission for LSD drug in anxiety after ‘another clear win’
biospace
20d
STAT+: GSK touts lung cancer data from two drugs
stat
20d
Definium says its LSD drug notched another Phase 3 win in anxiety disorder
endpoints
20d
STAT+: Definium’s LSD therapy eased anxiety in second large trial
stat
20d
Psychedelic therapies ride wave of public favor into FDA hearing
biospace
23d
Definium LSD drug goes 3 for 3 with another pivotal anxiety trial win
fiercebiotech
23d
Opinion: I’m a thoracic surgeon in New York City. For many of my patients, Sept. 11 is still not over
stat
24d
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
24d
Oz says ‘AI-based avatars’ can help rural communities. Some leaders disagree
stat
24d
Trump officials say AI will help save rural health care. Some leaders in the field don’t believe it
stat
24d
Opinion: John Fetterman’s post-stroke, politically problematic behaviors offer lessons about brain health on Capitol Hill
stat
25d
FDA to consider ‘innovative approaches’ to psychedelic drug development
raps
← prev
page 2 of 15
next →
